Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | F5 | P12259 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252668 | 0.92 | F10 (0.76) | F10F2F5 | |
| Hydrochloric Acid SCHEMBL1504551 | 0.91 | F10 (0.75) | F10F2F5 | |
| SCHEMBL12833557 | 0.84 | F10 (0.64) | F10F2F5 | |
| SCHEMBL31626925 | 0.80 | F10 (0.85) | F10F2F5 | |
| SCHEMBL1254080 | 0.80 | F10 (0.85) | F10F2F5 | |
| SCHEMBL14262214 | 0.80 | F10 (0.85) | F10F2F5 | |
| SCHEMBL3303356 | 0.79 | F10 (0.63) | F10F2F5 | |
| SCHEMBL1504249 | 0.79 | F10 (0.77) | F10F2F5 | |
| SCHEMBL14262206 | 0.79 | F10 (0.83) | F10F2F5 | |
| SCHEMBL3307789 | 0.79 | F10 (0.76) | F10F2F5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | APOTEX INC. (CA) | 2019-05-28 | — | — | US | disclosed |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | VKORC1, CYP2C9, VKORC1L1 | F10 26/4885F2 23/4885F5 40/4885 |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | VKORC1, CYP2C9, VKORC1L1 | F10 26/4885F2 23/4885F5 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.